Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Recent FDA Designations and Advancing Clinical Pipeline | DelveInsight

The 7MM Polycythemia Vera market size reached approximately USD 2 billion in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck, Italfarmaco, Ionis Pharmaceuticals, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell Bioscience and Disc Medicine, GluBio Therapeutics, and others are spearheading innovations in treatment approaches, addressing critical unmet needs in managing this chronic myeloproliferative neoplasm.

DelveInsight's report, titled "Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034", provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the polycythemia vera treatment landscape over the next decade.

In 2024, the United States dominated the polycythemia vera market, accounting for over 75% of the total market size, which amounts to USD 2 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum polycythemia vera market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions.

Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The report also provides historical as well as forecasted polycythemia vera epidemiology segmented by total polycythemia vera prevalent population, prevalent population of polycythemia vera based on symptoms, gender-specific prevalence of polycythemia vera, polycythemia vera prevalence by gene mutation, polycythemia vera prevalence based on risk, and age-specific prevalence of polycythemia vera in the 7MM.

The report estimates that the 7MM had approximately 320,000 polycythemia vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the PV patient share in 7MM is attributed to males, whereas 44% is attributed to females. Additionally, across all races and ethnicities, the polycythemia vera incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women.

Discover evolving trends in Polycythemia Vera patient pool forecasts @ https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Polycythemia vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the polycythemia vera management include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these polycythemia vera therapies.

While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight's report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action.

The report highlights that the polycythemia vera clinical pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutics), and others.

Unlock which emerging polycythemia vera drug is expected to capture the largest market share in 7MM by 2034. Visit the Polycythemia Vera Market Insights @ https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

In September 2025, the FDA awarded Breakthrough Therapy Designation to rusfertide for erythrocytosis in polycythemia vera. Furthermore, Rusfertide Phase 3 VERIFY trial results presented at ASCO 2025: These results demonstrated significant efficacy, with 76.9% of rusfertide-treated patients plus standard of care achieving a clinical response versus placebo. The topline results supported regulatory advancement and FDA designation.

In May 2025, Givinostat received FDA fast track status to support expedited review and regulatory support for patients needing innovative Polycythemia Vera therapy.

In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. The detailed results were presented at the ASCO 2025 Annual Meeting Plenary Session in June 2025, demonstrating rusfertide's ability to more than double clinical response rates across high- and low-risk PV groups.

Ionis Pharmaceuticals and Ono Pharmaceutical announced a global license agreement for sapablursen in polycythemia vera in March 2025.
Furthermore, in May 2025, the FDA has granted Fast Track designation to Italfarmaco's givinostat for polycythemia vera treatment, recognizing its potential to address an urgent unmet need in this rare blood cancer. These recent developments indicate positive momentum in the Polycythemia Vera treatment market.

Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight's analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation.

Related Reports
Polycythemia Vera Pipeline Insight [https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr]

Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine, among others.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

This release was published on openPR.